Samsung Bioepis, Teva Enter Commercialization Agreement on 6 Biosimilar Candidates
Samsung Bioepis will develop and make the biosimilars while Teva will sell them in major markets, including the United States, Europe and Canada.
8 Articles
8 Articles
Samsung Bioepis announced on the 1st that it has signed a sales cooperation agreement for biosimilars with global pharmaceutical company Teva Pharmaceutical Industries. The two companies plan to divide roles in the development and marketing of biosimilars for Fasenra and Ilaris. Samsung Bioepis will be responsible for the development, regulatory approval, and production of the Fasenra and Ilaris biosimilars, while Teva will handle sales in the U…
(Seoul = Yonhap News) Reporter Park Sang-hyun = Samsung Bioepis is strengthening cooperation with Teva Pharmaceutical Industries in the field of biosimilars.
Samsung Bioepis, Teva enter commercialization agreement on 6 biosimilar candidates
Samsung Bioepis and Teva Pharmaceutical Industries have entered into an agreement on commercializing the former’s up to six potential biosimilar candidates, including two confirmed investigational candidates, the companies said Thursday. According to Samsung Bioepis, the two sides have signed a global licensing, development and commercialization agreement for the potential candidates. Of them, two confirmed investigational biosimilar candidates …
Financial Post
India ShortsSamsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
The agreement covers SB41, a potential biosimilar candidate referencing Fasenra® (benralizumab), and SB44, a potential biosimilar candidate referencing Ilaris® (canakinumab) with an option for 4 additional assets The partnership will cover development and commercialization in the United States, Europe, and Canada, with an option to expand to other territories The partnership brings together Samsung Bioepis’ […]
Samsung Bioepis announced on the 1st that it has signed a partnership agreement with Teva Pharmaceutical Industries for two biosimilar candidates. The subjects of the agreement are 'SB41,' a biosimilar of Fasenra, and 'SB44,' a biosimilar of Ilaris. Through this agreement, both companies have agreed to cooperate closely throughout the entire process of the development and commercialization of these candidates. View of the new Samsung Bioepis h…
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to ...
Coverage Details
Bias Distribution
- 75% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
